These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 10454446)

  • 41. Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats.
    Linz W; Schölkens BA; Ganten D
    Clin Exp Hypertens A; 1989; 11(7):1325-50. PubMed ID: 2530011
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Management of hypertensive patients with cardiovascular damage].
    Tomiyama H; Takata Y; Yamashina A
    Nihon Rinsho; 2004 Mar; 62 Suppl 3():612-6. PubMed ID: 15171444
    [No Abstract]   [Full Text] [Related]  

  • 43. Stereology of cardiac hypertrophy induced by NO blockade in rats treated with enalapril and verapamil.
    Pereira LM; Mandarim-de-Lacerda CA
    Anal Quant Cytol Histol; 2001 Oct; 23(5):330-8. PubMed ID: 11693558
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of enalapril in rats with pressure overload cardiac hypertrophy.
    Di Paola Eugenio D; Pietro G; Rosario M; De Sarro G
    Gen Pharmacol; 1997 Apr; 28(4):531-3. PubMed ID: 9147021
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Goals of antihypertensive therapy.
    McVeigh GE; Flack J; Grimm R
    Drugs; 1995 Feb; 49(2):161-75. PubMed ID: 7729325
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reversal of interstitial fibroblast hyperplasia via apoptosis in hypertensive rat heart with valsartan or enalapril.
    Der Sarkissian S; Marchand EL; Duguay D; Hamet P; deBlois D
    Cardiovasc Res; 2003 Mar; 57(3):775-83. PubMed ID: 12618239
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Reduced periinfarction mortality as a result of long-term therapy with captopril but not hydralazine or propranolol in spontaneously hypertensive rats.
    Nguyen T; El Salibi E; Rouleau JL
    J Cardiovasc Pharmacol; 1998 Dec; 32(6):884-95. PubMed ID: 9869493
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Role of angiotensin II type 2 receptor during regression of cardiac hypertrophy in spontaneously hypertensive rats.
    Der Sarkissian S; Tea BS; Touyz RM; deBlois D; Hale TM
    J Am Soc Hypertens; 2013; 7(2):118-27. PubMed ID: 23414835
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Renoprotective effect of small doses of losartan and enalapril in patients with primary glomerulonephritis. Short-term observation.
    Tylicki L; Rutkowski P; Renke M; Rutkowski B
    Am J Nephrol; 2002; 22(4):356-62. PubMed ID: 12169868
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of antihypertensive therapy on left ventricular hypertrophy in essential hypertension.
    Frohlich ED
    Adv Nephrol Necker Hosp; 1990; 19():87-100. PubMed ID: 1967894
    [No Abstract]   [Full Text] [Related]  

  • 51. Additive effects of enalapril and losartan in (mREN-2)27 transgenic rats.
    Richer C; Bruneval P; Ménard J; Giudicelli JF
    Hypertension; 1998 Feb; 31(2):692-8. PubMed ID: 9461242
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Telemetry for cardiovascular monitoring in a pharmacological study: new approaches to data analysis.
    Anderson NH; Devlin AM; Graham D; Morton JJ; Hamilton CA; Reid JL; Schork NJ; Dominiczak AF
    Hypertension; 1999 Jan; 33(1 Pt 2):248-55. PubMed ID: 9931112
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Beta-adrenergic blockers and calcium antagonists in hypertrophic cardiomyopathy].
    Korovina EP
    Klin Med (Mosk); 1998; 76(12):30-5. PubMed ID: 10067289
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Changes of atrial natriuretic peptide and its messenger RNA with development and regression of cardiac hypertrophy in renovascular hypertensive rats.
    Matsubara H; Yamamoto J; Hirata Y; Mori Y; Oikawa S; Inada M
    Circ Res; 1990 Jan; 66(1):176-84. PubMed ID: 2136812
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of enalapril and hydralazine treatment and withdrawal upon cardiovascular hypertrophy in stroke-prone spontaneously hypertensive rats.
    King RA; Smith RM; Krishnan R; Cleary EG
    J Hypertens; 1992 Sep; 10(9):919-28. PubMed ID: 1328373
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Endothelin-1-induced vasopressor responses in essential hypertension.
    Kaasjager KA; Koomans HA; Rabelink TJ
    Hypertension; 1997 Jul; 30(1 Pt 1):15-21. PubMed ID: 9231815
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Hypertensive patients have to be doubly treated earlier. Which antihypertensive drug combination is appropriate to whom?].
    MMW Fortschr Med; 2003 May; 145(22):56. PubMed ID: 12866285
    [No Abstract]   [Full Text] [Related]  

  • 58. Time course of vascular structural changes during and after short-term antihypertensive treatment.
    Hale TM; Shoichet MJ; Bushfield TL; Adams MA
    Hypertension; 2003 Aug; 42(2):171-6. PubMed ID: 12810756
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Caspase-dependent cell death mediates the early phase of aortic hypertrophy regression in losartan-treated spontaneously hypertensive rats.
    Marchand EL; Der Sarkissian S; Hamet P; deBlois D
    Circ Res; 2003 Apr; 92(7):777-84. PubMed ID: 12623880
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Differential effects of antihypertensive drug therapy on arterial compliance.
    Resnick LM; Lester MH
    Am J Hypertens; 2002 Dec; 15(12):1096-100. PubMed ID: 12460707
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.